# Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

> **NCT03914170** · — · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 70 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Folfirinox + cetuximab

## Key facts

- **NCT ID:** NCT03914170
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2018-04-01
- **Final completion:** 2018-04-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03914170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03914170, "Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03914170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*